Bevacizumab biosimilar - Samsung Bioepis

Drug Profile

Bevacizumab biosimilar - Samsung Bioepis

Alternative Names: SB-8; SP-8

Latest Information Update: 28 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Samsung Bioepis
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • No development reported Cancer

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Belgium (IV, Infusion)
  • 01 Jun 2016 Phase-III clinical trials in Non-small cell lung cancer (Metastatic disease, Recurrent) in Georgia, South Korea (IV) (NCT02754882)
  • 13 Apr 2016 Phase-III clinical trials in Non-small cell lung cancer (Metastatic disease, Recurrent) in Spain, Poland, Germany (IV) after April 2016 (EudraCT2015-004026-34)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top